Technology News and Research

RSS

Teleflex first quarter net revenue increases 6% to $388.7 million

Teleflex Incorporated, a leading, global provider of medical technology products, today reported financial results for the three months ended March 27, 2011.

26 Apr 2011

KCI total revenue increases 3% to $501.2 million for first quarter 2011

Kinetic Concepts, Inc. today reported first quarter 2011 total revenue of $501.2 million, an increase of 3% from the first quarter of 2010. Foreign currency exchange movements had no significant impact on total revenue for the first quarter of 2011 as compared to the prior year.

26 Apr 2011

Senomyx receives U.S. patent for S2383 flavor ingredient

Senomyx, Inc., a leading company focused on using proprietary technologies to discover and develop novel flavor ingredients for the food, beverage, and ingredient supply industries, announced today that the Company has been granted U.S. Patent No. 7,928,111 covering foods and beverages containing S2383, a highly effective enhancer of the sweetener sucralose.

26 Apr 2011

Neusoft signs subscription agreement with Aerotel Medical Systems

Neusoft Corporation, a leading IT solution and service provider in China, recently announced that its wholly-owned subsidiary Neusoft Europe Inc. has signed a subscription agreement with Aerotel Medical Systems Ltd., a leading global manufacturer of modular, mobile and home based telemedicine and telecare solutions based in Israel, under which Neusoft Europe will subscribe for 26915 shares of Aerotel with 1.77 million US Dollars to hold 30.77% of its outstanding shares.

26 Apr 2011

Multipolar electrocoagulation is a safe, effective therapy for Barrett's esophagus

A new study reports that multipolar electrocoagulation in combination with acid suppression is a safe and effective method to ablate nondysplastic Barrett's esophagus over the long term.

26 Apr 2011

KemPharm to formulate and develop KP106 as oral film dosage for ADHD treatment

KemPharm, Inc. today announced that KP106, its clinical candidate for Attention Deficit/Hyperactivity Disorder, will be formulated and developed in an oral film dosage form pursuant to an exclusive collaboration agreement with MonoSol Rx relating to the development, commercialization and manufacture of KP106.

26 Apr 2011

Oxford Nanopore raises $41 million via private placement of ordinary shares

Oxford Nanopore Technologies Ltd., the UK-based developers of nanopore technology for the direct, electronic analysis of single molecules, today announced that it has raised £25 million in new funding via a private placement of ordinary shares in the Company.

From Oxford Nanopore Technologies 26 Apr 2011

New discoveries in stem-cell technology

A scientist at the Gladstone Institutes has made two significant stem-cell discoveries that advance medicine and human health by creating powerful new approaches for using stem cells and stem-cell-like technology.

26 Apr 2011

Aquilent launches new vaccine government site to help citizens stay healthy

Aquilent, the recognized leading provider of Web-based solutions shaping the next generation of technology for the federal government, today announced its development support role in the newly launched Vaccines.gov site, under contract with the U.S. Department of Health and Human Services.

26 Apr 2011

SI-BONE receives FDA approval for updated iFuse Implant System

SI-BONE, Inc., a medical device company that is pioneering the use of a minimally invasive surgical device to treat the sacroiliac joint announced the U.S. Food and Drug Administration approved a major modification to the existing product label.

26 Apr 2011

High computer use linked to increased engagement in MRB among adolescents

Researchers at Queen's University have found a strong association between computer and Internet use in adolescents and engagement in multiple-risk behaviours, including illicit drug use, drunkenness and unprotected sex.

26 Apr 2011

Kadmon Pharmaceuticals and Nano Terra announce worldwide licensing agreement

Kadmon Pharmaceuticals LLC, and Nano Terra, Inc., today announced that they have entered into an agreement under which Kadmon has been granted a perpetual, worldwide exclusive license to three novel, clinical-stage product candidates owned by Nano Terra as well as rights to Nano Terra’s drug discovery platform, Pharmacomer™ Technology. The product candidates and technology platform will be transferred to a newly formed joint venture, NT Life Sciences (“NT Life”), co-owned by Kadmon and Nano Terra, which will act as the licensor and recipient of any licensing or royalty fees subject to the agreement. Terms of the agreement were not disclosed.

25 Apr 2011

NovaSterilis novel vaccine patent

NovaSterilis Inc., a leader in the development and commercialization of supercritical carbon dioxide technology, has been granted US Patent 7,919,096. The patent, dated April 5th 2011, is entitled “Inactivating Organisms Using Carbon Dioxide At or Near Supercritical Pressure and Temperature Conditions.”

25 Apr 2011

Boston Scientific launches ION Paclitaxel-Eluting Platinum Chromium Coronary Stent System

Boston Scientific Corporation today announced U.S. Food and Drug Administration (FDA) approval and launch of the ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System, the Company's third-generation drug-eluting stent technology.

25 Apr 2011

Child's death renews medical error debate

News outlets examine efforts to end hospital errors and a different case may challenge laws that protect military medical personnel from medical malpractice lawsuits.

25 Apr 2011

MonoSol Rx, KemPharm enter development and commercialization partnership for ADHD prodrug

MonoSol Rx, LLC, the developer of PharmFilm® drug delivery technology, today announced that the Company has entered into a development and commercialization partnership with KemPharm, a biopharmaceutical company focused on the discovery and development of new, safer therapies for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), pain, and cardiovascular disease.

25 Apr 2011

PDI extends eDetailing to mobile programs

PDI, Inc. today announced that Group DCA has expanded its proprietary DIAGRAM™ software platform to enable eDetail delivery on popular mobile devices including the iPad®, iPod touch® and iPhone® and Android™-based phones.

25 Apr 2011

Pharmatek purchases spray dryer for drug formulation and manufacturing

Pharmatek Laboratories, Inc., a premier contract development and manufacturing organization supporting the pharmaceutical industry, announced that it has added spray drying to its drug formulation and manufacturing capabilities. The company has purchased a Buchi B-290 Mini Spray Dryer for formulation feasibility studies and small-scale clinical manufacture. This technology can be used for both oral and parenteral dosage forms.

25 Apr 2011

Pro-Pharmaceuticals receives method patent regarding DAVANAT in Japan

Pro-Pharmaceuticals, Inc., the leading developer of therapeutics that target Galectin proteins to treat cancer and fibrosis, today announced that the Japan Patent Office has accepted a new patent, No. 2002-574987, "Co-administration of a Polysaccharide with a Chemotherapy for the Treatment of Cancer". The patent protects, among other things, methods for reducing the toxicity of chemotherapies in which a polysaccharide, such as the Company's lead drug DAVANAT®, is co-administered with a chemotherapeutic agent to reduce toxicity of the chemotherapy.

25 Apr 2011

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

The Government of Rwanda, together with QIAGEN N.V. and Merck, known as MSD outside the United States and Canada, today announced the launch, in Kigali, Rwanda, of a comprehensive national cervical cancer prevention program that includes vaccination with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls 12 to 15 years of age and modern molecular diagnostic screening for women between the ages of 35 and 45.

From QIAGEN Manchester Limited 25 Apr 2011